Series Vol. 6 , 03 August 2023
* Author to whom correspondence should be addressed.
Asthma is one of the common chronic diseases in children, and so far there is no cure for asthma. Asthma sufferers are estimated to be more than 300 million people worldwide, and the number of asthma treatments is growing every year. In recent years, thanks to advances in therapeutic medicines, asthma symptoms can now be successfully controlled with inhaled corticosteroids and, if necessary, in combination with bronchodilators. However, even with maximum use of these drugs, the effect may be insufficient, and there are still some patients with refractory asthma that are not adequately controlled with general treatment. Drugs called biologics may become a drug that works well for previously poorly treated asthma and is recently available in children with severe asthma. Three biologics are currently available for use in children: omalizumab, mepolizumab (6 years and older), and dupilumab (12 years and older). However, there is still a lack of clinical research evidence for the specific clinical improvement rate. Therefore, in this study, this paper conducted a literature review on the latest clinical trials of biological agents at home and abroad, summarized the clinical trials of common biological agents, and introduced the latest treatment methods. The differences and deficiencies between each other achieve the effect of enhancing the prevention and cognition of asthma.
Asthma, childhood asthma, latest treatments, literature review, statistical methods
1. Roghaye Khasha and Mohammad Mehdi Sepehri, “Mobile GIS-based monitoring asthma attacks based on environmental factors” Journal of Cleaner Production, Volume 179, 417-428(1 April 2018)
2. Sankei Nishima and Masanari Kozawa, “Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children.” Asia Pac Allergy. 2019 Jan; 9(1): e7. Published online 2019 Jan 22.
3. Boulay ME, Morin A, Laprise C, Boulet LP. Asthma and rhinitis: what is the relationship? Curr Opin Allergy Clin Immunol. 2012; 12:449–454. [PubMed] [Google Scholar]
4. Hiroshi Odajima and MotohiroEbisawa, “Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy”, Allergology International, Volume 64, Issue 4, October 2015, Pages 364-370
5. Kenneth R Chapman and Frank C Albers, “The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma”, Allergy. 2019 Sep;74(9):1716-1726.
6. Atul Gupta and Isabelle Pouliquen, “Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma”, Pediatr Pulmonol. 2019 Dec;54(12):1957-1967.
7. Daniel J Jackson and Leonard B Bacharier, “Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomized, double-blind, placebo-controlled, parallel-group trial”, Lancet. 2022 Aug 13;400(10351):502-511.
8. Corrado Pelaia and Claudia Crimi, “Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy”, Biomedicines. 2021 Dec; 9(12): 1822. Published online 2021 Dec 3.
9. William W Busse and Eugene R Bleecker, “Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment”, J Allergy Clin Immunol. 2021 Jul;148(1):266-271.e2.
10. Leonard B Bacharier and Jorge F Maspero, “Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma”, N Engl J Med. 2021 Dec 9;385(24):2230-2240.
11. Michael E Wechsler and Amy D Klion, “Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis”, J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709.
12. Ya-Feng Yang and Xiao-Yan Wang, “Acupoint thread-embedding as adjuvant therapy for bronchial asthma in children and its effect on pulmonary function, serum IgA and IgE levels”, Zhongguo Zhen Jiu. 2021 Dec 12;41(12):1349-53.
13. Siriporn Wongwaree and Tassalapa Daengsuwan, “Comparison efficacy of randomized nebulized magnesium sulfate and ipratropium bromide/fenoterol in children with moderate to severe asthma exacerbation”, Asian Pac J Allergy Immunol. 2022 Mar;40(1):31-38.
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.